BioMarin Pharmaceutical (BMRN)
(Delayed Data from NSDQ)
$90.02 USD
0.00 (0.00%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $90.00 -0.02 (-0.02%) 7:58 PM ET
2-Buy of 5 2
D Value B Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$90.02 USD
0.00 (0.00%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $90.00 -0.02 (-0.02%) 7:58 PM ET
2-Buy of 5 2
D Value B Growth A Momentum B VGM
Zacks News
BioMarin (BMRN) Down 7.6% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks Industry Outlook Highlights BioMarin, Blueprint Medicines, Immunovant, Kymera and Ligand
by Zacks Equity Research
BioMarin, Blueprint Medicines, Immunovant, Kymera and Ligand have been highlighted in this Industry Outlook article.
5 Biotech Stocks Worth Adding to Your Portfolio in 2024
by Ekta Bagri
New drug approvals and pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position BMRN, BPMC, IMVT, KYMR and LGND well amid volatility.
BioMarin (BMRN) Beats on Q1 Earnings, Voxzogo Drives Sales
by Zacks Equity Research
BioMarin's (BMRN) earnings beat estimates in the first quarter of 2024, while revenues slightly miss the mark. The company maintains revenue guidance for 2024.
BioMarin (BMRN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for BioMarin (BMRN) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
BioMarin Pharmaceutical (BMRN) Tops Q1 Earnings Estimates
by Zacks Equity Research
BioMarin (BMRN) delivered earnings and revenue surprises of 18.33% and 0.14%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Is a Surprise Coming for BioMarin (BMRN) This Earnings Season?
by Zacks Equity Research
BioMarin (BMRN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
AstraZeneca (AZN) to Report Q1 Earnings: Here's What to Expect
by Zacks Equity Research
Sales of AstraZeneca's (AZN) key drugs like Imfinzi and Farxiga are expected to have been boosted by approvals in new indications.
Gear Up for BioMarin (BMRN) Q1 Earnings: Wall Street Estimates for Key Metrics
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for BioMarin (BMRN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024.
Novartis (NVS) to Report Q1 Earnings: What to Expect?
by Ekta Bagri
Novartis (NVS) key drugs Entresto, Kisqali and Pluvicto are likely to have fueled its top and bottom-line numbers in the first quarter.
Earnings Preview: Bristol Myers Squibb (BMY) Q1 Earnings Expected to Decline
by Zacks Equity Research
Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioMarin Pharmaceutical (BMRN) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
BioMarin (BMRN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is Beam Therapeutics (BEAM) Down 22.1% Since Last Earnings Report?
by Zacks Equity Research
Beam Therapeutics (BEAM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Atara Biotherapeutics (ATRA) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of 8.20% and 73.91%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
BioMarin (BMRN) Posts Q4 Earnings Beat, Upbeat Voxzogo Sales
by Zacks Equity Research
BioMarin (BMRN) reports encouraging fourth-quarter results, with earnings and sales beating estimates. The rapid uptake of Voxzogo boosts revenues.
Here's What Key Metrics Tell Us About BioMarin (BMRN) Q4 Earnings
by Zacks Equity Research
Although the revenue and EPS for BioMarin (BMRN) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
BioMarin Pharmaceutical (BMRN) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
BioMarin (BMRN) delivered earnings and revenue surprises of 11.36% and 1.49%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
5 Stocks Likely to Gain on Q4 Earnings Today After Market Close
by Nalak Das
We have narrowed our search to five large-cap stocks that are poised to beat on earnings today after market closes. These are: BKNG, AMH, FND, BMRN, PBA.
Biotech/Drug Stocks Q4 Earnings Due Feb 22: MRNA, BHC, NTLA, BMRN & More
by Ekta Bagri
Let us take a look at what's in store for biotech/drug stocks MRNA, BHC, NTLA, BMRN and ITCI, which are scheduled to report on Feb 22.
Merus N.V. (MRUS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Merus N.V. (MRUS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Seeking Clues to BioMarin (BMRN) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics
by Zacks Equity Research
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for BioMarin (BMRN), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2023.
BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
BioMarin (BMRN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Exact Sciences (EXAS) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
Exact Sciences' (EXAS) revenues in the fourth quarter of 2023 are likely to have been driven by its flagship cancer screening tests, Cologuard and Oncotype DX.
5 Biotech Stocks Likely to Outpace Q4 Earnings Estimates
by Kinjel Shah
Let us look at some drug/biotech stocks, MRNA, BMRN, AMRN, NTLA and BEAM, which are poised to beat on fourth-quarter earnings.
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.